Abstract
A silent revolution is taking place that has the potential to have an enormous impact on medicine, but it requires a high investment in technology and research before it can be of practical use. The reason for the silence is the high cost of the technology involved, putting it out of the reach of most academic centres. With the realisation that all of the human genes will be known and sequenced in the next few years, the next objective is to harness this information to identify new drug targets, to improve methods of diagnosis and to identify inherited genetic differences that increase the risk of developing particular diseases (Karp and Broder 1995). This will also facilitate analysis of the interaction of environmental factors and genetics. The way is being led by biotechnology and pharmaceutical companies and the larger institutes such as the National Cancer Institute (NCI). At the NCI, part of Klausner’s strategic planning was to establish the ‘genome anatomy project’ (see website http://inhouse.ncbi.nlm.nih.gov/ncicgap/). Such strategic planning was anathema to many scientists, but it must be the way forward in some areas of science where number crunching is the order of the day. Even though most doctors are not aware of the future applications, investors are clamouring to have a slice of the action, as indicated by a recent issue of Business Week that was devoted entirely to ‘The Biotech Century’. For academics wishing to be involved there is the difficulty that alone they cannot afford the capital costs, while by collaborating with industry it is difficult to get a deal that enables the information gained to go directly into the public domain. The NCI initiative is very important, as everything is being released over their website, including detailed protocols, and most of the current technology is being directed at diagnosing mutations in known genes or looking at mRNAs that are expressed in different disease states to obtain a profile or ‘index’ of the tissue or tumour involved (Brown and Hartwell 1998). The limitations are related to sensitivity and representation of the RNAs isolated from small numbers of cells where an amplification procedure is required. In addition, RNA levels do not directly relate to protein expression, and studies of RNA will not identify mutations or subtle changes in proteins that may be of more importance, such as phosphorylation and glycosylation. Many companies in the last 2 years have therefore started to direct their attention to expression profiling at the protein level, and if the difficulties of sensitivity can be overcome, this may prove to be the best way forward for some applications (Strachan et al. 1997).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ahmadian M, Wistuba II, Fong KM, Behrens C, Kodagoda DR, Saboorian MH, Shay J, Tom-linson GE, Blum J, Minna JD, Gazdar AF (1997) Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res 57:3664–3668
Aldaz CM, Chen T, Sahin A, Cunningham D, Bondy M (1995) Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res 55:3976–3981
Brown PO, Hartwell L (1998) Genomics and human disease — variations on variation. Nat Genet 18:91–93
Cahill DP, Lengauer C, Yu J, Riggins GJ, Willison JKV, Markowitz SD, Kinzler KW, Vogelstein B (1998) Mutations of mitotic checkpoint genes in human cancers. Nature 392:300–303
Chen T, Dhingra K, Sahin A, Sneige N, Hortobagyi G, Aldaz CM (1996 a) Technical approach for the study of the genetic evolution of breast cancer from paraffin-embedded tissue sections. Breast Cancer Res Treat 39:177–185
Chen T, Sahin A, Aldaz CM (1996b) Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region. Cancer Res 56:5605–5609
Chester KA, Begent RHJ, Robson L, Keep P, Pedley RB, Boden JA, Boxer G, Green A, Winter G, Cochet O, Hawkins RE (1994) Phage libraries for generation of clinically useful antibodies. Lancet 343:455–456
Courjal F, Theiller C (1997) Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. Cancer Res 57:4368–4377
Crook T, Crossland S, Crompton MR, Osin P, Gusterson BA (1997) P53 mutations in BRCA1-associated familial breast cancer. Lancet 350:638–639
De Risi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, Trent JM (1996) Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 14:457–460
Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA, Liotta LA (1996) Laser capture microdissection. Science 274:998–1001
Franzen B, Linder S, Alaya AA, Eriksson E, Fujioka K, Bergman AC, Jornvall H, Auer G (1997) Analysis of polypeptide expression in benign and malignant human breast lesions. Electrophoresis 18(3/4):582–587
Folkman J (1971) Tumour angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186
Fisher ER, Constantino J, Fisher B, Palekar AS, Paik SM, Suarez CM, Wolmark N, for the National Surgical Adjuvant Breast and Bowel Collaborating Investigators (1996) Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) protocol B-17. Five-year observations concerning lobular carcinoma in situ. Cancer 78:1403–1416
Gauther SA, Mangion J, Russel P, Seal S, Barfoot R, Ponder BA, Stratto M, Easton D (1997) Variation of risk of breast and ovarian cancer associated with germline mutations of the BRCA2 gene. Nat Genet 15:103–105
Guildford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE (1998) E-cadherin germline mutations in familial gastric cancer. Nature 392:402–405
Gusterson BA (1993) The role of the pathologist in dissecting the biology of breast cancer with special reference to in situ disease. Eur J Cancer 2:51–58
Hacia JG, Brody LC, Chee MS, Fodor SPA, Collins FS (1996) Detection of the heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis. Nat Genet 14:441–456
James LA, Mitchell ELD, Menasce L, Varley JM (1997) Comparative genomic hybridisation of ductal carcinoma in situ of the breast: identification of regions of DNA amplification and deletion in common with invasive breast cancer. Oncogene 14:1059–1065
Kallioniemi A, Pekka O, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW, Waldman F (1994) Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA 91:2156–2160
Karp JE, Broder S (1995) Molecular foundations of cancer: new targets for intervention. Nat Med 1:309–320
Kerangueven F, Noguchi T, Coulier F, Allione F, Wargniez V, Simony-Lafontaine J, Longy M, Jacquemier J, Sobol H, Eisinger F, Birnbaum D (1997) Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res 57:5469–5474
Kuukasjärvi T, Tanner M, Pennanen S, Karhu R, Kallioniemi OP, Isola J (1997) Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. Am J Pathol 150:1465–1471
Lakhani SR, Collins N, Sloane JP, Stratton MR (1995 a) Loss of heterozygosity in lobular carcinoma in situ of the breast. J Clin Pathol 48:M74–M78
Lakhani SR, Collins N, Stratton MR, Sloane JP (1995 b) Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol 48:611–615
Lakhani SR, Slack DN, Hamoudi RA, Collins N, Stratton MR, Sloane JP (1996) Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. Lab Invest 74:1–7
Marshall A, Hodgson J (1998) DNA chips: an array of possibilities. Nat Biotechnol 16:27–31
Nayar R, Zhuang Z, Merino MJ, Silverberg SG (1997) Loss of heterozygosity on chromosome 11q13 in lobular lesions of the breast using tissue microdissection and polymerase chain reaction. Hum Pathol 28:277–282
Nishizaki T, Chew K, Chu L, Isola J, Kallioniemi A, Wedner N, Waldman FM (1997) Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer 74:513–517
Osin P, Lu YJ, Lakhani S, Pilotti S, Gusterson BA, Shipley J (1998) Gains and losses of genomic material in atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) of the breast suggest these lesions represent a similar stage of tumour progression. J Pathol Suppl 184:15a
Rasmussen RK, Ji H, Eddes JS, Moritz RL, Reid GE, Simpson RJ, Dorow DS (1997) Two-dimensional electrophoretic analysis of human breast carcinoma proteins: mapping of proteins that bind to the SH3 domain of mixed lineage kinase MLK2. Electrophoresis 18:588–598
Schafer AJ, Hawkins JR (1998) DNA variation and the future of human genetics. Nat Biotechnol 16:33–39
Steeg PS, Clare SE, Lawrence JA, Zhou Q (1996) Molecular analysis of premalignant and carcinoma in situ lesions of the human breast. Am J Pathol 149:733–738
Strachan T, Abitol M, Davidson D, Beckmann JS (1997) A new dimension for the human genome project: towards comprehensive expression maps. Nat Genet 16:126–132
Telenius H, Carter NP, Bebb CE, Nordenskjold M, Ponder BA, Tunnacliffe A (1992) Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. Genomics 13:718–725
Tirkkonen M, Tanner M, Kahru R, Kallionemi A, Isola J, Kallionemi OP (1998) Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 21:177–184
Veldman T, Vignon C, Schröck E, Rowley JD, Ried T (1997) Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping. Nat Genet 15:406–410
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Osin, P., Shipley, J., Lu, Y.J., Crook, T., Gusterson, B.A. (1998). Experimental Pathology and Breast Cancer Genetics: New Technologies. In: Senn, HJ., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Primary Breast Cancer VI. Recent Results in Cancer Research, vol 152. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45769-2_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-45769-2_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-45771-5
Online ISBN: 978-3-642-45769-2
eBook Packages: Springer Book Archive